

# Luca Pinzi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/273683/publications.pdf>

Version: 2024-02-01

26  
papers

1,503  
citations

623574

14  
h-index

642610

23  
g-index

28  
all docs

28  
docs citations

28  
times ranked

1492  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dual Targeting Strategies on Histone Deacetylase 6 (HDAC6) and Heat Shock Protein 90 (Hsp90). <i>Current Medicinal Chemistry</i> , 2022, 29, 1474-1502.	1.2	11
2	On the development of B-Raf inhibitors acting through innovative mechanisms. <i>F1000Research</i> , 2022, 11, 237.	0.8	1
3	Inhibitors of histone deacetylase 6 based on a novel 3-hydroxy-isoxazole zinc binding group. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2021, 36, 2080-2086.	2.5	5
4	Drug Repurposing and Polypharmacology to Fight SARS-CoV-2 Through Inhibition of the Main Protease. <i>Frontiers in Pharmacology</i> , 2021, 12, 636989.	1.6	28
5	Prediction of activity and selectivity profiles of human Carbonic Anhydrase inhibitors using machine learning classification models. <i>Journal of Cheminformatics</i> , 2021, 13, 18.	2.8	12
6	Antifungal Activity and DNA Topoisomerase Inhibition of Hydrolysable Tannins from <i>Punica granatum</i> L.. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4175.	1.8	21
7	LigAdvisor: a versatile and user-friendly web-platform for drug design. <i>Nucleic Acids Research</i> , 2021, 49, W326-W335.	6.5	12
8	Cheminformatics Analyses of Tau Ligands Reveal Key Molecular Requirements for the Identification of Potential Drug Candidates against Tauopathies. <i>Molecules</i> , 2021, 26, 5039.	1.7	6
9	Hydroxamic Acid Derivatives: From Synthetic Strategies to Medicinal Chemistry Applications. <i>ACS Omega</i> , 2021, 6, 21843-21849.	1.6	42
10	Design and Synthesis of Hsp90 Inhibitors with Bâ€Raf and PDHK1 Multiâ€Target Activity. <i>ChemistryOpen</i> , 2021, 10, 1177-1185.	0.9	5
11	Identification of Target Associations for Polypharmacology from Analysis of Crystallographic Ligands of the Protein Data Bank. <i>Journal of Chemical Information and Modeling</i> , 2020, 60, 372-390.	2.5	19
12	Repositioning Natural Products in Drug Discovery. <i>Molecules</i> , 2020, 25, 1154.	1.7	34
13	Design of Dual Inhibitors of Histone Deacetylase 6 and Heat Shock Protein 90. <i>ACS Omega</i> , 2020, 5, 11473-11480.	1.6	27
14	In Silico Repositioning of Cannabigerol as a Novel Inhibitor of the Enoyl Acyl Carrier Protein (ACP) Reductase (InhA). <i>Molecules</i> , 2019, 24, 2567.	1.7	22
15	Refinement and Rescoring of Virtual Screening Results. <i>Frontiers in Chemistry</i> , 2019, 7, 498.	1.8	48
16	Molecular Docking: Shifting Paradigms in Drug Discovery. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4331.	1.8	890
17	Evaluation of Amides, Carbamates, Sulfonamides, and Ureas of 4-Prop-2-ynylidenecycloalkylamine as Potent, Selective, and Bioavailable Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 1246-1273.	2.9	5
18	Identification of 4â€arylâ€1<i>H</i>â€pyrrole[2,3â€b]pyridine derivatives for the development of new Bâ€Raf inhibitors. <i>Chemical Biology and Drug Design</i> , 2018, 92, 1382-1386.	1.5	3

#	ARTICLE	IF	CITATIONS
19	Structure-Activity Relationships of Hexahydrocyclopenta[ <i>c</i> ]quinoline Derivatives as Allosteric Inhibitors of CDK2 and EGFR. <i>ChemMedChem</i> , 2018, 13, 2627-2634.	1.6	23
20	Identification of small-molecule EGFR allosteric inhibitors by high-throughput docking. <i>Future Medicinal Chemistry</i> , 2018, 10, 1545-1553.	1.1	21
21	Selection of protein conformations for structure-based polypharmacology studies. <i>Drug Discovery Today</i> , 2018, 23, 1889-1896.	3.2	22
22	On the Integration of In Silico Drug Design Methods for Drug Repurposing. <i>Frontiers in Pharmacology</i> , 2017, 8, 298.	1.6	178
23	Computational polypharmacology comes of age. <i>Frontiers in Pharmacology</i> , 2015, 6, 157.	1.6	61
24	Identification of potential biological targets of oxindole scaffolds via in silico repositioning strategies. <i>F1000Research</i> , 0, 11, 217.	0.8	0
25	Identification of potential biological targets of oxindole scaffolds via in silico repositioning strategies. <i>F1000Research</i> , 0, 11, 217.	0.8	0
26	On the development of B-Raf inhibitors acting through innovative mechanisms. <i>F1000Research</i> , 0, 11, 237.	0.8	4